Plain-English translation of NCT06876883 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The MIRACLE study is tracking patients who have been diagnosed with moderate to severe mitral regurgitation—a condition where the heart's mitral valve doesn't close properly, allowing blood to leak backward. Researchers will collect detailed heart imaging and health information to better understand which patients are at highest risk for serious complications like heart failure. The goal is to create a tool that helps doctors predict outcomes and make better treatment decisions for people with this valve problem.
Untreated severe mitral regurgitation can lead to heart failure and life-threatening complications, but doctors don't always know which patients will develop these problems. This study exists to identify the warning signs and risk factors that predict who will have the worst outcomes, so treatment can be personalized and started at the right time.
You likely qualify if…
You likely don't qualify if…
As a participant, you will undergo a comprehensive heart ultrasound (echocardiogram) at the beginning of the study to measure how your valve is working and how your heart is pumping. Researchers will collect detailed information about your heart function, blood pressure in your lungs, and other measurements. After that, the study team will follow your health over time through medical records and periodic check-ins to track whether you develop heart failure or other complications.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Enrollment target
~2,000 participants
Started
June 2016
Primary completion
June 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaodong Zhuang, MD
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.